0.3500USD0.00%Mkt Cap: —P/E: —Last update: 2026-05-22
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that i…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-17.54M USD
Revenue/Share—
Last Price0.3500 USD
Fiscal Year End—
MR Quarter—
Employees13
CountryUS
SectorHealth Care
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.16
EPS (TTM)—
EPS (Forward)—
52W Range
0.3300100% of range0.3500
52W High0.3500 USD
52W Low0.3300 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-92.27%
ROA-81.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.03M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-12.80M USD
Net Debt/EBITDA0.63
Balance Sheet
Debt/Equity0.02
Current Ratio9.97
Quick Ratio9.02
Book Value/Sh2.069 USD
Cash/Share1.737 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float7.50M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)0
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—